nfcol.net Neurofibromatosis Clinical Reference · EN / ES
NF1 Criteria NF2 & SWN MEK Therapy Checkup Schedule Archive
EN · Español
Clinical Handbook › Annual Surveillance Calendar

Age-by-Age NF1 Surveillance Schedule (Infancy Through Adulthood)

Evidence-based annual clinical visits aligned with the American Academy of Pediatrics (AAP) and European Reference Network (ERN GENTURIS), highlighting essential checks alongside unnecessary tests to avoid.

Consensus Guidelines: AAP (Pediatrics 2019) & ERN GENTURIS (Eur J Med Genet 2023)
Clinician measuring upper-arm blood pressure cuff on a patient in a sunlit outpatient genetics examination room

1. Lifespan Surveillance Matrix (0 to 50+ Years)

Core Principle of NF1 Follow-Up: Targeted annual clinical, ophthalmic, and blood-pressure examinations catch treatable NF1 complications early, whereas routine sedated brain MRIs in asymptomatic toddlers do not improve visual outcomes and are advised against by AAP guidelines.

Because each NF1 manifestation follows a predictable biological age window (Miller et al., AAP 2019), knowing what leaves the risk window is just as reassuring as knowing what enters it:

Age Window Mandatory Annual / Semi-Annual Assessments Tests NOT Needed Routinely (If Asymptomatic)
Infancy (0–2 yr) Inspect shins for anterolateral tibial bowing; pediatric neuro-ophthalmology every 6–12 mo; head circumference & growth chart (NF1-specific macrocephaly awareness); paired NF1/SPRED1 sequencing if pigment-only. No routine sedated brain MRI if eye exams are normal; avoid CT scans completely.
Early Childhood (3–8 yr) Quantitative age-matched visual acuity + OCT retinal nerve fiber layer (RNFL) thickness every 12 mo (peak OPG onset <7 yr); annual blood pressure (renal artery stenosis); pre-school executive function, attention & phonics screening. No routine repeated spot counting once diagnosis is established.
Adolescence (9–17 yr) Annual Adam forward-bend spine check for dystrophic scoliosis; Tanner staging (screen precocious or delayed puberty); blood pressure; assess plexiform neurofibromas for MEK therapy; transition readiness. Ophthalmic OPG screening spacing widens to every 1–2 yr after age 8–10 if baseline vision is normal.
Adults (18–50+ yr) Women: Annual contrast breast MRI starting at age 30 (± mammogram per ERN GENTURIS/NCCN, as breast cancer risk is elevated 4–5× between ages 30 and 50); annual BP & plasma metanephrines if paroxysmal hypertension/headaches (pheochromocytoma); baseline whole-body MRI at transition (ages 16–20) to quantify internal tumor burden; vitamin D & bone density (DEXA). Routine annual PET/CT is not indicated unless a plexiform lesion develops pain, growth, or hardening.

2. Two Frequently Overlooked Checks: Renovascular BP and Learning Support

  • Why Every Child & Adult Needs Annual Blood Pressure Measurement: NF1 vasculopathy causes fibromuscular renal artery stenosis in children/young adults (treatable via angioplasty) and adrenal pheochromocytoma in adults (~1%–5%, which MUST be screened before elective surgery or pregnancy if hypertension, palpitations, or sweating occur).
  • Neurodevelopmental Profile (50%–60% of NF1 Children): Overall IQ typically lies within the normal range (mean ~90), yet specific challenges in sustained attention (ADHD phenotype, ~35%–40%, often responsive to methylphenidate), visuospatial organization, executive planning, and motor coordination are common. Proactive school accommodations (504/IEP plans) at age 4–6 prevent secondary academic frustration.

Frequently Asked Clinical Questions

Should an asymptomatic 2-year-old with NF1 have a routine screening brain MRI under anesthesia?

American Academy of Pediatrics (AAP) guidelines recommend against routine screening brain MRIs in asymptomatic young children with NF1, relying instead on regular pediatric neuro-ophthalmology exams and OCT imaging.

At what age do women with NF1 begin breast cancer MRI screening?

International guidelines (NCCN and ERN GENTURIS) recommend starting annual breast MRI screening at age 30 for women with NF1, ten years earlier than average-risk screening, because elevated NF1 breast cancer risk concentrates between ages 30 and 50.

Key Consensus Guidelines & Primary Sources

  1. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506–1513. PubMed 34012067.
  2. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genetics in Medicine. 2022;24(9):1967–1977. PubMed 35674741.
  3. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430–1442. PubMed 32187457.
  4. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025;43(7):758–769. PubMed 39514828.
  5. Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1 (American Academy of Pediatrics). Pediatrics. 2019;143(5):e20190660. PubMed 30988031.